Page last updated: 2024-10-15

gdp-4-keto-6-deoxymannose

Description

GDP-4-dehydro-6-deoxy-alpha-D-mannose : A GDP-sugar having 4-dehydro-6-deoxy-alpha-D-mannose as the sugar portion. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID135398621
CHEBI ID16955
SCHEMBL ID151947
MeSH IDM0154280

Synonyms (26)

Synonym
guanosine 5'-(trihydrogen diphosphate), p'-(6-deoxy-alpha-d-lyxo-hexopyranos-4-ulos-1-yl) ester
18186-48-6
CHEBI:16955
guanosine 5'-[3-(6-deoxy-alpha-d-lyxo-hexopyranosyl-4-ulose) dihydrogen diphosphate]
guanosine diphosphate-4-keto-6-deoxy-d-mannose
gdp-4-dehydro-d-rhamnose
gdp-4-dehydro-6-deoxy-alpha-d-mannose
gdp-4-keto-6-deoxymannose
C01222 ,
GDP-4-DEHYDRO-6-DEOXY-D-MANNOSE ,
gdp-4-dehydro-6-deoxy-d-talose
gdp-4-oxo-6-deoxy-d-mannose
gdp-4-keto-6-deoxy-d-mannose
[[(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3s,4r,6r)-3,4-dihydroxy-6-methyl-5-oxooxan-2-yl] hydrogen phosphate
SCHEMBL151947
{[(2r,3s,4r,5r)-5-(2-amino-6-oxo-6,9-dihydro-1h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}[({[(2r,3s,4r,6r)-3,4-dihydroxy-6-methyl-5-oxooxan-2-yl]oxy}(hydroxy)phosphoryl)oxy]phosphinic acid
gdp-4-keto-6-d-deoxymannose
gdp-4-oxo-6-deoxymannose
gdp-4-keto-6deoxymannose
PNHLMHWWFOPQLK-BKUUWRAGSA-N
Q27102151
[[(2~{r},3~{s},4~{r},5~{r})-5-(2-azanyl-6-oxidanylidene-1~{h}-purin-9-yl)-3,4-bis(oxidanyl)oxolan-2-yl]methoxy-oxidanyl-phosphoryl] [(2~{r},3~{s},4~{r},6~{r})-6-methyl-3,4-bis(oxidanyl)-5-oxidanylidene-oxan-2-yl] hydrogen phosphate
f7e ,
[[(2r,3s,4r,5r)-5-(2-amino-6-oxo-1h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3s,4r,6r)-3,4-dihydroxy-6-methyl-5-oxooxan-2-yl] hydrogen phosphate
[(2s,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-[[(2r,3r,4s,6s)-3,4
DTXSID60864645
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
GDP-sugar
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (13)

PathwayProteinsCompounds
Metabolism of proteins1058144
Post-translational protein modification666112
Asparagine N-linked glycosylation16478
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein5068
Synthesis of substrates in N-glycan biosythesis3756
GDP-fucose biosynthesis616
GDP-L-fucose biosynthesis I (from GDP-D-mannose)18
Fructose and Mannose metabolism ( Fructose and Mannose metabolism )2527
NADP+ + GDP-L-fucose = NADPH + GDP-4-dehydro-6-deoxy-D-mannose ( Fructose and Mannose metabolism )14
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
Fructose and mannose metabolism014
Colanic acid building blocks biosynthesis014
GDP-D-rhamnose biosynthesis05
GDP-L-fucose biosynthesis I (from GDP-D-mannose)16

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (12.50)18.7374
1990's1 (12.50)18.2507
2000's5 (62.50)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]